Improving Patient
Outcomes in
Solid Tumor
Cancer TreatmentBIO300
A New Class of Cancer Drug
COVID-19
BIO300
Preventing long term lung damage caused by inflammation
Keeping America Safe
BIO300
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism
Humanetics News
01.25.2021
Humanetics Corporation Receives Funding from Department of Defense to Test Drug Against COVID-19
Read More
10.20.2020
Humanetics Corporation Presents New Data at the Radiation Research Society Meeting
Read More
10.08.20
Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. Talks with KTTV TV in Los Angeles about COVID-19's Lingering Effects and BIO 300's Clinical Trial
Watch the Interview
10.08.20
MassLive.com Interviews Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. about BIO 300 and Linking Radiation to Coronavirus in Effort to Help "Long Haulers"
Read the Article
10.06.20
Spectrum News 14 Speaks to Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. about BIO 300
Watch the Interview
10.01.20
Humanetics Board Member Vice Admiral Matthew L. Nathan, M.D. discusses BIO 300 and Treating COVID "Long Haulers" with WRAZ TV
Watch the Interview
09.29.20
Humanetics CEO Ron Zenk Talks to the Sun Current about BIO 300's Post-COVID-19 Lung Trial
Read More
09.15.20
Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Board of Directors
Read More
07.23.20
Humanetics CEO Ron Zenk Previews Upcoming BIO 300 COVID-19 Clinical Trial with WCCO TV
Watch the Interview
07.23.20
Humanetics Corporation Receives Funding from NIAID to Test BIO 300 in COVID-19 Patients
Read More
05.28.20
Humanetics Corporation Invited for Oral Presentation at Annual Meeting of American Society of Radiation Oncologists
Read More
02.19.20
Humanetics Acquires Manufacturing Assets for Radioprotectant Drug
Read More
05.06.20
Dr. Colin Chinn, Former Staff Surgeon, Joins Medical Advisory Board
Read More